Global Health Care Sector

Strategy Highlights

  • The Global Health Care Sector strategy is benchmarked to the Russell 3000® Health Care Index.
  • The strategy seeks companies that address unmet medical needs or improve the delivery of care.
  • Portfolios are actively managed using a bottom-up investment approach and do not attempt to time the markets.
  • Portfolios are typically fully invested in predominantly health care companies, generally holding less than 5% cash.
  • Portfolios generally hold between 50 and 80 stocks, with no one stock typically exceeding 10% of a total portfolio.
  • The strategy is supported by a team comprised of financial investment professionals and advanced scientific degree holders.
  • The firm’s Biotech Fellowship onboards Ph.D. and M.D. candidates to reinforce the team’s deep scientific research.

Objective

The objective of the Global Health Care Sector strategy is to outperform the Russell 3000® Health Care Index over a complete market cycle. The Strategy aims to generate medium-and long-term capital growth by actively investing in companies within the global health care market.  The Strategy seeks to invest in companies that can address an unmet medical need or improve the delivery of care. We believe these attributes drive sustainable competitive advantages, which afford companies a greater opportunity to generate high returns and we look to invest at prices that do not adequately reflect their potential value.

Global Health Care Sector | Annualized Returns as of 6/30/2026

† Not Annualized. Source: Ridgeline

Quarterly Fact Sheet

Download a detailed quarterly strategy fact sheet (pdf). Download PDF

Ryan Dunnegan, CPA, Portfolio Manager, Assistant Portfolio Manager, Research Analyst
Anna Bunn, Ph.D., Assistant Portfolio Manager, Research Analyst
Wilson Lin, Research Analyst

Kennedy Capital Management LLC (“KCM”) is a Delaware limited liability company headquartered in Missouri. KCM is registered as an investment adviser with the Securities and Exchange Commission under the Investment Advisers Act of 1940. Registration with the SEC does not imply any level of skill or training. Clients of the Firm include U.S. corporations, pension and profit sharing funds, colleges and universities, trusts, not-for-profit organizations, foundations, and individuals.  KCM claims compliance with the Global Investment Performance Standards (GIPS®).  GIPS® is a registered trademark of CFA Institute. CFA Institute does not endorse or promote this organization, nor does it warrant the accuracy or quality of the content contained herein.  (GIPS®) are a set of standardized, industry-wide ethical principles that provide investment firms with guidance on calculating and reporting their investment results to prospective clients to ensure fair representation and full disclosure of an investment firm’s performance history.

Although the statements of fact and data in this report have been obtained from, and are based upon, sources that the Firm believes to be reliable, we do not guarantee their accuracy, and any such information may be incomplete or condensed.  All opinions included in this report constitute the Firm’s judgment as of the date of this report and are subject to change without notice.  This report is for informational purposes only and is not intended as an offer or solicitation with respect to the purchase or sale of any security. All investing entails substantial risk.  A complete list of all securities recommended by KCM in the preceding year, a fully compliant GIPS composite report, and the list of composite descriptions are available upon request from KCM at 10829 Olive Blvd., Suite 100. St. Louis, MO, 63141.

Investing in the stock market involves gains and losses and may not be suitable for all investors. Investing in equity securities is speculative and involves substantial risk.  Small cap and mid cap securities may involve more risk than larger-cap securities.  Investments concentrated in sector or specific industry may involve greater risk and volatility than more diversified investments.  

The Global Health Care Sector Strategy Composite seeks to generate medium- and long-term capital growth by actively investing in companies within the global health care market. The Strategy invests in companies that address unmet medical needs or improve the delivery of care. We believe these companies are uniquely positioned to generate significant returns and we look to invest at prices that do not adequately reflect their potential value. Market capitalization of the securities purchased in the strategy will generally be reflective of the Russell 3000® Health Care Index as defined by FTSE Russell®. The U.S. Dollar is the currency used to express performance.

Composite specific data provided within this presentation has been calculated from accounts that are discretionary as defined in this paragraph.  The assets shown are derived only from discretionary accounts.  Non-discretionary accounts, as defined by KCM, are accounts that are not included in the composite due to one or any combination of the following criteria: there were significant cash inflows or outflows within the account; the account’s asset level did not meet the minimum requirement to remain in the composite; the account assets are managed by others using our non-discretionary model.  The temporary removal of such an account occurs at the beginning of the month and the account re-enters the composite the month after the criteria has been met.

Returns are presented gross and net of investment advisory fees and include the reinvestment of all income. Gross of fees returns reflect the deduction of transaction costs and custodian fees but do not reflect the deduction of investment advisory fees.  Net of fee performance is calculated using gross returns less the actual applicable annual management fee applied monthly.  Past performance is not indicative of future results. A client’s return will be reduced by the advisory fees as described in Form ADV Part 2A and other expenses incurred by the account.  For example, an annual advisory fee of 1% compounded quarterly over 10 years will reduce a gross 14.44% annual return to a net 13.32% annual return.  Form ADV Part 2A is available upon request.  

The performance figures reported herein are unaudited, may be based upon information obtained via electronic data sources (”feeds”) and may be subject to change.  Data feeds from many of KCM clients’ selected custodians are obtained through third party sources and are used to compare custodial data to KCM’s client account records as frequently as daily.  Monthly, KCM reviews clients’ account holdings along with cash and share quantities against the custodial statements.  In some instances, variances may exist between final audited custodial information and the information KCM obtains via such data feeds. Generally, any such variances are researched and reconciled within thirty days of the period end.

Russell Investment Group is the source and owner of the Russell Index data contained or reflected in this material and all trademarks and copyrights related thereto.  The presentation may contain confidential information and unauthorized use, disclosure, copying, dissemination or redistribution is strictly prohibited.  This is a presentation of Kennedy Capital Management.  Russell Investment Group is not responsible for the formatting or configuration of this material or for any inaccuracy in Kennedy Capital Management’s presentation thereof.

The Russell 3000® Health Care Index is an unmanaged index representative of companies involved in medical services or health care in the Russell 3000 Index, which is comprised of the 3,000 largest U.S. companies as determined by total market capitalization. The Russell 3000® Index measures the performance of the broad segment of the U.S. equity universe comprised of the largest 3000 U.S. companies representing approximately 98% of the investable U.S. equity market.

The Russell 3000® Health Care Index as defined by FTSE Russell® is used as the benchmark. The Index is unmanaged and represents total returns including reinvestment of dividends. The benchmark is used for comparative purposes only and generally reflects the comparable risk or investment style of the Firm’s strategy. The investment portfolios underlying the Index are different from the investments in the portfolios managed by the Firm. Certain accounts may also use other benchmarks not listed in the GIPS composite report. The Verification and Performance Examination Report does not cover the benchmark returns included in the GIPS composite report.  Investors cannot invest directly in an Index.

Ryan Dunnegan, CPA

Portfolio Manager, Assistant Portfolio Manager, Research Analyst

Ryan Dunnegan, CPA, Portfolio Manager, Assistant Portfolio Manager, Research Analyst
RYAN DUNNEGAN, CPA, Portfolio Manager for the Global Health Care and Biotechnology Sector strategies, Assistant Portfolio Manager for the Small Cap Growth and SMID Cap Growth strategies, and Research Analyst. As a Research Analyst at KCM, Mr. Dunnegan is responsible for selecting and monitoring securities within the health care sector of KCM's universe. Ryan also manages the Equity Research Internship Program.  Mr. Dunnegan began his investment career at KCM in 2006 during a two-year internship. Ryan subsequently transitioned to the role of Associate Equity Analyst with KCM in 2008 through 2009, while simultaneously earning his Master of Accounting degree. Following completion of his master's degree, Mr. Dunnegan spent nearly four years at KPMG LLP where he provided audit services in accordance with U.S. GAAP and IFRS standards to an array of public and privately held global companies. Ryan earned both his B.S. in Business Administration with a concentration in Accounting and a Master of Accounting from Saint Louis University.

Anna Bunn, Ph.D.

Assistant Portfolio Manager, Research Analyst

Anna Bunn, Ph.D., Assistant Portfolio Manager, Research Analyst
ANNA Bunn, Ph.D., Assistant Portfolio Manager for the Micro Cap Opportunities, Micro Cap, Global Health Care, and Biotechnology Sector strategies and Research Analyst. As a Research Analyst, Anna is responsible for selecting and monitoring securities within the health care sector of KCM’s universe. Anna joined KCM in January 2023 after gaining experience in equity analysis through the firm’s Biotechnology Equity Research Fellowship, a program she now manages at the firm. Anna graduated magna cum laude earning a B.A. in Neuroscience from The College of Wooster and a Ph.D. in Biology and Biomedical Sciences (Neuroscience) from Washington University. Anna’s doctoral research included both preclinical and clinical studies, with a focus on neuro-oncology.

Wilson Lin

Research Analyst

Wilson Lin, Research Analyst
WILSON LIN, Research Analyst, is responsible for selecting and monitoring securities within the health care sector of KCM’s universe.  Mr. Lin started at KCM as an intern in February 2020 and progressed through the program ending his internship as Head Equity Research Intern.  Wilson earned his B.S. in Finance and International Business from Saint Louis University.